Mereo is an innovative leader in the specialty biopharma sector with a focus on acquiring, developing and optimising the value of innovative medicines designed to address significant unmet medical needs in rare and specialty disease areas, and improve patient quality of life.
Why partner with us?
The founders of Mereo have a broad experience of acquiring and managing portfolios of products from pharmaceutical companies including from Astra Zeneca and Novartis. This includes the accounting, legal and operational aspects key to success.
Mereo was incorporated in March 2015 and joined the London Stock Exchange’s AIM market in June 2016. Since incorporation, Mereo has raised over £105 million from institutional investors, including the leading healthcare investors Woodford, Invesco and from Novartis. In addition, in August 2017, a £20 million debt facility was agreed with Silicon Valley Bank and Kreos Capital of which £10 million has been drawn down.
The Founders of Mereo have strong relationships with a broad range of global pharmaceutical companies to source new product candidates and facilitate their acquisition and licensing as exemplified by those with Novartis and Astra Zeneca. The deals are structured to be mutually beneficial to each party.
Through its internal resources with deep clinical experience in rare and specialty diseases from Phase I through approval, combined with working with external CRO’s, Mereo is able to offer a comprehensive, seamless and scalable development capability facilitating rapid transfer and start-up of clinical programmes from pharmaceutical partners.
The company’s internal resource have been carefully assembled to achieve an optimum balance of financial and clinical expertise, equipping it to source strong new product candidates while effectively supporting those in its current portfolio. This is also balanced by the use of external experts as required on an intermittent basis.
Mereo has developed a clear set of selection criteria for new product candidates which reflect the expertise and experience of its founders as follows:
- Medicines addressing unmet medical need with compelling market potential, preferably in specialty or rare indications
- A strong scientific rationale and a comprehensive and robust package of clinically-meaningful data (proof of concept)
- A clear clinical and regulatory strategy
- A favourable competitive landscape, pricing and reimbursement positioning
- A clear, defined and financeable clinical trial route to value-creating milestones.